A. Implementing Request for Advice Process for pCODR

Currently, CADTH's CDR includes a request for advice (RFA) process that enables public drug plans to seek advice from the CADTH Canadian Drug Expert Committee (CDEC) regarding a previous CDEC Final Recommendation. This is set out in accordance with the *Procedure for the CADTH Common Drug Review*.

In view of this, CADTH is expanding this process by implementing an RFA process for the pCODR program to support participating jurisdictions by enabling them to seek advice from the pCODR Expert Review Committee (pERC) in limited instances where a final recommendation has been issued by pERC and the recommendation has received a notification to implement. For example, it may apply in cases where there may be challenges with implementing criteria that were associated with a pERC final recommendation which had not been previously identified at the time of the review. Similar to the CDR process, an RFA must relate back to a previous pERC final recommendation.

Key Highlights of the RFA Process for pCODR

- An RFA will be initiated when CADTH receives a written request made by the participating jurisdictions (i.e., pCODR Advisory Committee [PAC] and/or Provincial Advisory Group [PAG]) that clearly describes the issues for the request regarding a previous pERC Final Recommendation. In response to the request, pERC will issue a Record of Advice, which may or may not result in a new pERC recommendation.

- The RFA request will be posted on the CADTH website. Stakeholders (e.g., submitter/manufacturer, patient groups and registered clinician[s]) who provided input on the original submission in question will have an opportunity to comment on the RFA request posed to pERC. Eligible stakeholders will have 10 business days from the posting date to provide comments.

- The placement of the RFA on the pERC meeting agenda will be in the following order:
    - any Submission undergoing a procedural review
    - any Submission meeting priority review criteria
    - any Resubmission meeting priority review criteria
    - Submissions for New Oncology Drug Submissions or Oncology Drugs with a New Indication (Pre-NOC, Pre-NOC/c, Post NOC, or Post-NOC/c)
    - an **RFA**
    - Reconsiderations of an Initial Recommendation
    - Resubmissions.

- Similar to the CDR process, an RFA would not be assigned to the review queue.

- An RFA process can only be initiated after a pERC final recommendation has been issued a notification to implement and will not be subject to a procedural review.

The following describes the RFA process that will be applied to the pCODR program: